Deals
Penumbra Sales Rise 15% But Operating Income Is Flat At $130.0 Million, And Boston Scientific Deal Moves To 2027
Nine-month operating income matched last year as SG&A climbed 23.5%, and Penumbra now expects its merger to close in early 2027.
Penumbra (PEN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Deals
Nine-month operating income matched last year as SG&A climbed 23.5%, and Penumbra now expects its merger to close in early 2027.
Earnings
Selling costs outran sales, and with the Boston Scientific deal pending, the company will give no 2026 outlook and hold no call.